Sagimet (SGMT) CFO receives 50,000 options at $7.27 exercise price
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Sagimet Biosciences granted its Chief Financial Officer, Thierry Chauche, a stock option to acquire 50,000 shares of Series A Common Stock. The option has a $7.27 per-share exercise price and expires on May 27, 2036.
According to the filing, these options vest in 48 equal monthly installments beginning after May 28, 2026, contingent on his continued service. Following this grant, Chauche holds 50,000 stock options directly, reflecting routine equity-based compensation rather than an open-market transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Chauche Thierry
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 50,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 50,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 50,000 options
Exercise price: $7.27 per share
Expiration date: May 27, 2036
+2 more
5 metrics
Stock options granted
50,000 options
Grant of stock options to CFO Thierry Chauche
Exercise price
$7.27 per share
Exercise price for Series A Common Stock underlying the options
Expiration date
May 27, 2036
Option expiration for the 50,000-share grant
Vesting schedule
48 monthly installments
Vesting over 48 equal monthly installments after May 28, 2026
Derivative holdings after grant
50,000 derivative securities
Total stock options held directly following the reported transaction
Key Terms
Stock Option (Right to Buy), Series A Common Stock, exercise price, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"Security title is listed as Stock Option (Right to Buy) for the grant"
Series A Common Stock financial
"The underlying security title is stated as Series A Common Stock"
Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.
exercise price financial
"The option carries a $7.2700 per-share conversion or exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares underlying this option shall vest over forty-eight equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative security financial
"The transaction is categorized as a derivative-type transaction in the summary"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What did Sagimet Biosciences (SGMT) disclose about its CFO in this Form 4?
Sagimet Biosciences disclosed that CFO Thierry Chauche received a grant of 50,000 stock options. These options relate to Series A Common Stock and form part of his equity-based compensation, rather than an open-market purchase or sale of existing shares.
How many stock options did Sagimet (SGMT) grant to CFO Thierry Chauche?
Sagimet granted CFO Thierry Chauche stock options for 50,000 underlying shares of Series A Common Stock. This single award represents his reported post-transaction derivative holdings, as the filing shows 50,000 derivative securities owned directly after the grant transaction.
What is the exercise price of the Sagimet (SGMT) CFO’s new stock options?
The exercise price of the CFO’s new stock options is $7.27 per share. This means Chauche can purchase Series A Common Stock at $7.27 once options vest and are exercised, regardless of the future market trading price at that time.
When do the Sagimet (SGMT) CFO’s 50,000 stock options vest?
The 50,000 stock options vest over 48 equal monthly installments following May 28, 2026. Each month a portion becomes exercisable, but vesting depends on Thierry Chauche’s continued service with Sagimet on each monthly vesting date described in the award footnote.
When do the newly granted Sagimet (SGMT) CFO stock options expire?
The newly granted stock options to Sagimet’s CFO expire on May 27, 2036. If not exercised by that expiration date, the right to purchase the 50,000 underlying Series A Common Stock shares at the $7.27 exercise price will lapse completely.